Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors
Authors:
- Valentina MagriVMValentina Magri
- Gianluigi De RenziGRGianluigi De Renzi
- Luca MarinoLuca Marino
- Michela De MeoMichela De Meo
- Marco SiringoMSMarco Siringo
- Alain GelibterAGAlain Gelibter
- Roberta GareriRGRoberta Gareri
- Chiara CataldiCCChiara Cataldi
- Giuseppe GianniniGGGiuseppe Giannini
- Daniele SantiniDaniele Santini
- Chiara NicolazzoChiara Nicolazzo
- Paola GazzanigaPGPaola Gazzaniga
Open Access
- 28 March 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3752
Abstract
Evidence has been provided that circulating cancer-associated macrophage-like cell (CAM-L) numbers increase in response to chemotherapy, with an inverse trend compared to circulating tumor cells (CTCs). In the era of evolving cancer immunotherapy, whether CAM-Ls might have a potential role as predictive biomarkers of response has been unexplored. We evaluated whether a serial blood evaluation of CTC to CAM-L ratio might predict response to immune checkpoint inhibitors in a cohort of non-small-cell lung cancer patients. At baseline, CTCs, CAM-Ls, and the CTC/CAM-L ratio significantly correlate with both progression-free survival (PFS) and overall survival (OS). The baseline CTC/CAM-L ratio was significantly different in early progressors (4.28 ± 3.21) compared to long responders (0.42 ± 0.47) (p = 0.001). In patients treated with immune checkpoint inhibitors, a CTC/CAM-L ratio ≤ 0.25 at baseline is associated with better PFS and OS. A baseline CTC/CAM-L ratio ≤ 0.25 is statistically significant to discriminate early progressions from durable response. The results of the present pilot study suggest that CAM-Ls together with CTCs could play an important role in evaluating patients treated with cancer immunotherapy.Keywords
Funding Information
- Sapienza University of Rome (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
- European Commission (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
- ECS 0000024 Rome Technopole (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
- European Union–NextGenerationEU (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
This publication has 36 references indexed in Scilit:
- Progresses in biomarkers for cancer immunotherapyMedcomm, 2023
- Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population ScreeningJAMA Internal Medicine, 2023
- Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screeningBiosensors and Bioelectronics, 2023
- Novel targets for immune-checkpoint inhibition in cancerCancer Treatment Reviews, 2023
- Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancerProstate Cancer and Prostatic Diseases, 2020
- The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cellsSeminars in Cancer Biology, 2020
- EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancerEuropean Journal of Cancer, 2019
- Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancerBreast Cancer Research and Treatment, 2017
- Image based Machine Learning for identification of macrophage subsetsScientific Reports, 2017
- Challenges in circulating tumor cell detection by the CellSearch systemMolecular Oncology, 2015